Table 1. Clinical characteristics of patients with ERONs.

Case no.	Histology	Age (years)	FIGO Stage	Residual tumor	Recurrence		ARID1A	p53	POLE	PTEN	PIK3CA	KRAS
1	E	58	IIIC	N	Y		M	WT	M	WT	WT	NA
2	E	57	IIIC	Y	Y		M	WT	WT	WT	WT	NA
3	E	72	IIIC	N	Y		M	M	M	M	WT	WT
4	E	60	IV	Y	Y		M	M	M	NA	WT	WT
5	E	80	IA	N	Y		WT	WT	WT	NA	WT	WT
6	E	59	IC	N	N		M	WT	WT	M	M	WT
7	E	58	IA	N	N		M	WT	WT	M	M	WT
8	E	61	IIC	N	N		M	WT	M	M	WT	NA
9	E	50	IC	N	N		M	M	WT	M	WT	M
10	E	47	IC	N	N		M	WT	M	WT	WT	NA
11	E	77	IC	N	N		M	M	M	M	WT	W
12	E	58	IC	N	N		M	WT	WT	M	WT	NA
13	E	76	IC	N	N		M	M	WT	NA	WT	NA
14	C	56	IV	Y	Y		M	NA	M	WT	NA	NA
15	C	63	IC	N	Y		M	WT	WT	M	WT	NA
16	C	55	IIIC	Y	Y		M	M	M	M	M	WT
17	C	50	IC	N	N		NA	NA	WT	WT	NA	NA
18	C	62	IC	N	Y		M	WT	M	M	WT	NA
19	C	61	IV	Y	Y		M	M	WT	M	WT	WT
20	C	50	IC	N	N		NA	NA	WT	WT	NA	NA
21	C	71	IC	N	N		M	WT	WT	M	WT	WT
22	C	55	IC	N	Y		M	WT	WT	M	WT	NA
					Mutation frequency %		95	36.8	40.9	68.4	15.8	11.1
					Previous Reports %	E C	30(15) (16) 46-57(15)(16)	9(20)(21) 25(20)(21)	20(18) 8(18)	8(7)(9)	20(22) (23) 33-46(22 )(23)	10(24)(25)

NA: Not available.

WT: Wild type.

M: Mutation.

E: endometroid carcinoma.

C: clear cell carcinoma.